Paper42076830
Qiling Hushen Formula Ameliorates Type 2 Diabetic Kidney Disease via Gut-Kidney Axis Restoration and TLR4/NF-κB/NLRP3 Suppression.
Wang Y and 9 others. J Diabetes Res, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Qiling Hushen Formula Ameliorates Type 2 Diabetic Kidney Disease via Gut-Kidney Axis Restoration and TLR4/NF-κB/NLRP3 Suppression. Papers, record 42076830. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42076830
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Qiling Hushen Formula Ameliorates Type 2 Diabetic Kidney Disease via Gut-Kidney Axis Restoration and TLR4/NF-κB/NLRP3 Suppression.
- PubMed
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diabetes Mellitus, Type 2 | Major topic |
| Diabetic Nephropathies | Major topic |
| Toll-Like Receptor 4 | Major topic |
| NF-kappa B | Major topic |
| NLR Family, Pyrin Domain-Containing 3 Protein | Major topic |
| Gastrointestinal Microbiome | Major topic |
| Kidney | Major topic |
| Drugs, Chinese Herbal | Major topic |
| Animals | |
| Mice | |
| Diabetes Mellitus, Experimental | |
| Chromatography, Liquid | |
| Tandem Mass Spectrometry | |
| Mice, Inbred C57BL | |
| Proteinuria | |
| Intestinal Barrier Function | |
| Cytokines | |
| RNA, Ribosomal, 16S | |
| Bacteria | |
| Male | |
| Colon | |
| Lipopolysaccharides |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82374386 | National Natural Science Foundation of China | PubMed |
Source PubMed
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38565643 | Short-chain fatty acids: linking diet, the microbiome and immunity. | Nat Rev Immunol | 2024 | https://conductscience.org/library/papers/38565643 | PubMed |
| 2 | 42076830 | Qiling Hushen Formula Ameliorates Type 2 Diabetic Kidney Disease via Gut-Kidney Axis Restoration and TLR4/NF-κB/NLRP3 Suppression. | J Diabetes Res | 2026 | https://conductscience.org/library/papers/42076830 | PubMed |
| 3 | 32973502 | Resveratrol Modulates the Gut Microbiota and Inflammation to Protect Against Diabetic Nephropathy in Mice. | Front Pharmacol | 2020 | https://conductscience.org/library/papers/32973502 | PubMed |
| 4 | 36794950 | A Novel Synbiotic Alleviates Autoimmune Hepatitis by Modulating the Gut Microbiota-Liver Axis and Inhibiting the Hepatic TLR4/NF-κB/NLRP3 Signaling Pathway. | mSystems | 2023 | https://conductscience.org/library/papers/36794950 | PubMed |
| 5 | 34604258 | Qing-Re-Xiao-Zheng Formula Modulates Gut Microbiota and Inhibits Inflammation in Mice With Diabetic Kidney Disease. | Front Med (Lausanne) | 2021 | https://conductscience.org/library/papers/34604258 | PubMed |
| 6 | 30273931 | Inflammation in Diabetic Kidney Disease. | Nephron | 2019 | https://conductscience.org/library/papers/30273931 | PubMed |
| 7 | 35661785 | Molecular mechanisms and therapeutic targets for diabetic kidney disease. | Kidney Int | 2022 | https://conductscience.org/library/papers/35661785 | PubMed |
| 8 | 37804821 | Astragalus membranaceus and Salvia miltiorrhiza ameliorate diabetic kidney disease via the "gut-kidney axis". | Phytomedicine | 2023 | https://conductscience.org/library/papers/37804821 | PubMed |
| 9 | 40384385 | Shen Shuai II Recipe alleviates renal fibrosis in chronic kidney disease by improving of hypoxia and inhibition of TLR4/MyD88/NF-κB/NLRP3 pathway. | Ren Fail | 2025 | https://conductscience.org/library/papers/40384385 | PubMed |
| 10 | 34124032 | An Overview of the Posttranslational Modifications and Related Molecular Mechanisms in Diabetic Nephropathy. | Front Cell Dev Biol | 2021 | https://conductscience.org/library/papers/34124032 | PubMed |
| 11 | 33280239 | Complement C5 activation promotes type 2 diabetic kidney disease via activating STAT3 pathway and disrupting the gut-kidney axis. | J Cell Mol Med | 2021 | https://conductscience.org/library/papers/33280239 | PubMed |
| 12 | 38625103 | Phlorizin Limits Bovine Viral Diarrhea Virus Infection in Mice via Regulating Gut Microbiota Composition. | J Agric Food Chem | 2024 | https://conductscience.org/library/papers/38625103 | PubMed |
| 13 | 35490491 | Protective mechanism of traditional Chinese medicine guizhi fuling pills against carbon tetrachloride-induced kidney damage is through inhibiting oxidative stress, inflammation and regulating the intestinal flora. | Phytomedicine | 2022 | https://conductscience.org/library/papers/35490491 | PubMed |
| 14 | 37364420 | FTZ polysaccharides ameliorate kidney injury in diabetic mice by regulating gut-kidney axis. | Phytomedicine | 2023 | https://conductscience.org/library/papers/37364420 | PubMed |
| 15 | 36239349 | Enterorenal crosstalks in diabetic nephropathy and novel therapeutics targeting the gut microbiota. | Acta Biochim Biophys Sin (Shanghai) | 2022 | https://conductscience.org/library/papers/36239349 | PubMed |
| 16 | 32758603 | Polysaccharides from Armillariella tabescens mycelia ameliorate renal damage in type 2 diabetic mice. | Int J Biol Macromol | 2020 | https://conductscience.org/library/papers/32758603 | PubMed |
| 17 | 36787845 | Yi-Shen-Hua-Shi granule ameliorates diabetic kidney disease by the "gut-kidney axis". | J Ethnopharmacol | 2023 | https://conductscience.org/library/papers/36787845 | PubMed |
| 18 | 36966849 | A proteoglycan isolated from Ganoderma lucidum attenuates diabetic kidney disease by inhibiting oxidative stress-induced renal fibrosis both in vitro and in vivo. | J Ethnopharmacol | 2023 | https://conductscience.org/library/papers/36966849 | PubMed |
| 19 | 36863097 | Macrophage inflammatory protein-1β as a novel therapeutic target for renal protection in diabetic kidney disease. | Biomed Pharmacother | 2023 | https://conductscience.org/library/papers/36863097 | PubMed |
| 20 | 36583468 | Abelmoschus Manihot ameliorates the levels of circulating metabolites in diabetic nephropathy by modulating gut microbiota in non-obese diabetes mice. | Microb Biotechnol | 2023 | https://conductscience.org/library/papers/36583468 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42812582 | Global Research Trends in Traditional Chinese Medicine for Diabetic Kidney Disease: A 20-Year Bibliometric Analysis. | J Inflamm Res | 2026 | https://conductscience.org/library/papers/42812582 | PubMed |
| 42076830 | Qiling Hushen Formula Ameliorates Type 2 Diabetic Kidney Disease via Gut-Kidney Axis Restoration and TLR4/NF-κB/NLRP3 Suppression. | J Diabetes Res | 2026 | https://conductscience.org/library/papers/42076830 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42076830
GET https://conductscience.org/api/papers/v1/42076830/references?page=2